Eversheds Sutherland Sweden advised Neola Medical on its SEK 20 million directed share issue, welcoming the company’s first institutional investors
April 15, 2025
Eversheds Sutherland Sweden advised Neola Medical on its SEK 20 million directed share issue, welcoming the company’s first institutional investorsApril 15, 2025 Neola Medical AB (publ) revolutionizes neonatal intensive care with Neola®—a medical device enabling continuous lung monitoring and real-time alerts for life-threatening complications using advanced technology to measure lung volume changes and oxygen concentration. The proceeds from the share issue will support ongoing clinical studies on preterm babies and preparations for the planned FDA application for Neola® in the U.S. Eversheds Sutherland’s team consisted of Johan Engström, Kevin Holmkvist and Hanna Ullerholt. Handelsbanken acted as Sole Manager and Bookrunner in connection with the directed share issue. Key contacts
Latest Insights
Latest News
Latest Eventsclient news June 03, 2026 A blueprint for growth: Eversheds Sutherland supports Leonard Design Group ... client news June 02, 2026 Next stop, public ownership: Eversheds Sutherland advises DfT on GTR transi... firm news June 01, 2026 Eversheds Sutherland strengthens restructuring offering with senior partner... firm news June 01, 2026 |